One-month exposure to soy isoflavones did not induce the ability to produce equol in postmenopausal women
- PMID: 16482068
- DOI: 10.1038/sj.ejcn.1602415
One-month exposure to soy isoflavones did not induce the ability to produce equol in postmenopausal women
Abstract
Objective: As more and more postmenopausal women are taking soy isoflavone supplementation for relieving menopausal symptoms, we investigated the impact of chronic exposure on their bioavailability, with focus on achievable plasma concentrations and potential stimulation of the capacity to produce equol.
Subjects: A total of 12 Caucasian postmenopausal women.
Intervention: Volunteers ingested 100 mg isoflavones/day (aglycone equivalents, in cereal bars and yoghurts) for 1 month. Plasma concentrations of metabolites at 2, 4, 6, 8, 10, 12 and 24 h postdose, as well as urinary excretion in fractions over 36 h were compared between days 1 and 30.
Results: Similar plasma kinetic curves were obtained at day 1 and day 30 for genistein and daidzein. Maximum plasma concentrations were 1.68+/-0.68 micromol/l on day 1 compared to 2.27+/-0.76 micromol/l on day 30 for daidzein (P=0.056), and 3.88+/-1.50 micromol/l on day 1 compared to 5.30+/-2.38 micromol/l on day 30 for genistein (P=0.091). Urinary excretion of daidzein and genistein did not differ significantly between days 1 and 30. Maximum plasma concentration of equol increased significantly from 0.31+/-0.27 to 0.99+/-0.51 micromol/l for equol-producer volunteers (P=0.046). However, the seven volunteers who were classified as non-equol producers on day 1 did not acquire the ability to produce equol after 1-month exposure.
Conclusions: Chronic exposure to isoflavones in postmenopausal women resulted in plasma concentrations as high as 2.5-5 micromol/l of each isoflavone, but did not induce the ability to produce equol.
Published online 15 February 2006.
Similar articles
-
Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production.J Pharm Biomed Anal. 2007 Mar 12;43(4):1488-94. doi: 10.1016/j.jpba.2006.10.006. Epub 2006 Nov 15. J Pharm Biomed Anal. 2007. PMID: 17110073 Clinical Trial.
-
Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women.J Negat Results Biomed. 2006 Aug 14;5:11. doi: 10.1186/1477-5751-5-11. J Negat Results Biomed. 2006. PMID: 16907966 Free PMC article. Clinical Trial.
-
Increased probiotic yogurt or resistant starch intake does not affect isoflavone bioavailability in subjects consuming a high soy diet.Nutrition. 2007 Oct;23(10):709-18. doi: 10.1016/j.nut.2007.06.010. Epub 2007 Jul 26. Nutrition. 2007. PMID: 17656069 Clinical Trial.
-
Review of the factors affecting bioavailability of soy isoflavones in humans.Nutr Cancer. 2007;57(1):1-10. doi: 10.1080/01635580701267677. Nutr Cancer. 2007. PMID: 17516857 Review.
-
Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol-producing phenotype?Nutr Rev. 2007 Jun;65(6 Pt 1):294-9. doi: 10.1301/nr.2007.jun.294-299. Nutr Rev. 2007. PMID: 17605306 Review.
Cited by
-
Flavonoid intake is associated with lower all-cause and disease-specific mortality: The National Health and Nutrition Examination Survey 2007-2010 and 2017-2018.Front Nutr. 2023 Feb 14;10:1046998. doi: 10.3389/fnut.2023.1046998. eCollection 2023. Front Nutr. 2023. PMID: 36866051 Free PMC article.
-
Equol inhibits growth, induces atresia, and inhibits steroidogenesis of mouse antral follicles in vitro.Toxicol Appl Pharmacol. 2016 Mar 15;295:47-55. doi: 10.1016/j.taap.2016.02.009. Epub 2016 Feb 11. Toxicol Appl Pharmacol. 2016. PMID: 26876617 Free PMC article.
-
Effect of soy isoflavones supplement on climacteric symptoms, bone biomarkers, and quality of life in Korean postmenopausal women: a randomized clinical trial.Nutr Res Pract. 2017 Jun;11(3):223-231. doi: 10.4162/nrp.2017.11.3.223. Epub 2017 Apr 20. Nutr Res Pract. 2017. PMID: 28584579 Free PMC article.
-
Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production.Nutrients. 2019 Feb 19;11(2):433. doi: 10.3390/nu11020433. Nutrients. 2019. PMID: 30791484 Free PMC article.
-
Effects of an equol-containing supplement on advanced glycation end products, visceral fat and climacteric symptoms in postmenopausal women: A randomized controlled trial.PLoS One. 2021 Sep 10;16(9):e0257332. doi: 10.1371/journal.pone.0257332. eCollection 2021. PLoS One. 2021. PMID: 34506596 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials